Literature DB >> 7838526

HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation.

M Thomas1, P Massimi, J Jenkins, L Banks.   

Abstract

A key activity of the p53 protein during suppression of cell growth is its ability to stimulate transcription from promoters of cellular genes which contain a p53 responsive element. The E6 proteins from the oncogenic associated Human Papillomaviruses (HPVs) have been shown to inhibit specifically the p53 transcriptional activation and this has been proposed as a mechanism whereby the virus prevents the suppression of cell cycle progression and the induction of apoptosis. However, the mechanism by which E6 exercises this function is unknown, as is the ability of E6 to associate with different oligomeric forms of p53. In this study we demonstrate that E6 induces changes within the p53 protein which result both in inhibition of DNA binding and in dissociation of p53 protein previously bound to the DNA. These activities correlate exactly with the ability of E6 to inhibit p53 transcriptional activation and are independent of the ability of E6 to direct the degradation of the p53 protein. Further, we show that E6 labels wild type tetrameric and dimeric forms of p53 proteins for ubiquitin mediated degradation more readily than monomeric forms of the protein. However, in vivo analyses indicate that E6 is capable of inhibiting the transcriptional activation induced by the tetrameric, dimeric and monomeric forms of p53.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7838526

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

Review 1.  Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses.

Authors:  Aloysius J Klingelhutz; Ann Roman
Journal:  Virology       Date:  2012-01-27       Impact factor: 3.616

2.  Telomerase activation in cervical cancer.

Authors:  S Anderson; K Shera; J Ihle; L Billman; B Goff; B Greer; H Tamimi; J McDougall; A Klingelhutz
Journal:  Am J Pathol       Date:  1997-07       Impact factor: 4.307

3.  Phosphorylation drives an apoptotic protein to activate antiapoptotic genes: paradigm of influenza A matrix 1 protein function.

Authors:  Umesh Chandra Halder; Rahul Bhowmick; Tapasi Roy Mukherjee; Mukti Kant Nayak; Mamta Chawla-Sarkar
Journal:  J Biol Chem       Date:  2013-04-02       Impact factor: 5.157

4.  Human Papillomavirus infection requires the CCT Chaperonin Complex.

Authors:  Marina Bugnon Valdano; Paola Massimi; Justyna Broniarczyk; David Pim; Michael Myers; Daniela Gardiol; Lawrence Banks
Journal:  J Virol       Date:  2021-03-17       Impact factor: 5.103

5.  HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation.

Authors:  M Thomas; B Glaunsinger; D Pim; R Javier; L Banks
Journal:  Oncogene       Date:  2001-09-06       Impact factor: 9.867

6.  The human papillomavirus type 16 E6 oncoprotein can down-regulate p53 activity by targeting the transcriptional coactivator CBP/p300.

Authors:  H Zimmermann; R Degenkolbe; H U Bernard; M J O'Connor
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

7.  p53 suppression overwhelms DNA polymerase eta deficiency in determining the cellular UV DNA damage response.

Authors:  Rebecca R Laposa; Luzviminda Feeney; Eileen Crowley; Sebastien de Feraudy; James E Cleaver
Journal:  DNA Repair (Amst)       Date:  2007-09-05

Review 8.  Papillomavirus E6 proteins.

Authors:  Heather L Howie; Rachel A Katzenellenbogen; Denise A Galloway
Journal:  Virology       Date:  2008-12-10       Impact factor: 3.616

9.  Identification of two novel functional p53 responsive elements in the herpes simplex virus-1 genome.

Authors:  Jui-Cheng Hsieh; Ryan Kuta; Courtney R Armour; Paul E Boehmer
Journal:  Virology       Date:  2014-05-29       Impact factor: 3.616

10.  Proteasomal degradation of p53 by human papillomavirus E6 oncoprotein relies on the structural integrity of p53 core domain.

Authors:  Xavier Bernard; Philip Robinson; Yves Nominé; Murielle Masson; Sebastian Charbonnier; Juan Ramon Ramirez-Ramos; Francois Deryckere; Gilles Travé; Georges Orfanoudakis
Journal:  PLoS One       Date:  2011-10-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.